List of Excipients in Branded Drug EQUALINE 12 HOUR DECONGESTANT

Generic Drugs Containing EQUALINE 12 HOUR DECONGESTANT

Company	Ingredient	NDC	Excipient
United Natural Foods Inc dba UNFI	pseudoephedrine hydrochloride	41163-054	CARNAUBA WAX
United Natural Foods Inc dba UNFI	pseudoephedrine hydrochloride	41163-054	CELLULOSE, MICROCRYSTALLINE
United Natural Foods Inc dba UNFI	pseudoephedrine hydrochloride	41163-054	DIBASIC CALCIUM PHOSPHATE DIHYDRATE

What are the Most Frequently-Used Excipients in EQUALINE 12 HOUR DECONGESTANT?

# Of NDCs	Excipient
1	CARNAUBA WAX
1	CELLULOSE, MICROCRYSTALLINE
1	DIBASIC CALCIUM PHOSPHATE DIHYDRATE

Last updated: September 8, 2026

EQUALINE 12 Hour Decongestant is a pseudoephedrine hydrochloride extended-release OTC product whose commercial value depends more on excipient-controlled release, manufacturing reliability, and retail execution than on proprietary drug substance rights. The main opportunities are lower-cost controlled-release platforms, improved tablet robustness, packaging optimized for pseudoephedrine controls, and differentiated combination products. The product has limited patent protection because pseudoephedrine and conventional extended-release technologies are mature.

EQUALINE 12 Hour Decongestant Excipient Strategy and Commercial Opportunities

EQUALINE 12 Hour Decongestant is generally marketed as pseudoephedrine hydrochloride extended-release tablets, typically containing 120 mg of pseudoephedrine hydrochloride with a 12-hour dosing interval. The product is regulated as an OTC nasal decongestant under the FDA monograph framework rather than through a newly approved product-specific NDA.[1]

Its excipient strategy must support four commercial requirements:

1. Controlled pseudoephedrine release over approximately 12 hours.
2. Consistent dissolution and bioavailability across manufacturing lots.
3. Tablet durability during high-volume retail distribution.
4. Compliance with pseudoephedrine sales, packaging, and recordkeeping requirements.

The product has little conventional patent moat. Competitive advantage is more likely to come from cost, supply continuity, dosage-form quality, combination-product positioning, and retailer distribution.

What is EQUALINE 12 Hour Decongestant and which active ingredient does it contain?

EQUALINE 12 Hour Decongestant is a long-acting oral nasal decongestant based on pseudoephedrine hydrochloride. Pseudoephedrine is an alpha-adrenergic agonist that reduces nasal mucosal swelling through vasoconstriction.[1]

A typical product profile is:

Attribute	Product profile
Brand	EQUALINE 12 Hour Decongestant
Active ingredient	Pseudoephedrine hydrochloride
Typical strength	120 mg per extended-release tablet
Dosage form	Extended-release oral tablet
Dosing interval	Approximately every 12 hours
Therapeutic category	Nasal decongestant
Regulatory pathway	OTC monograph-based product
Primary competitors	Sudafed 12 Hour, store-brand pseudoephedrine ER products
Patent position	Mature active ingredient with limited current product-specific patent value
Key commercial constraint	Federal and state pseudoephedrine sales controls

The exact inactive-ingredient composition can vary by manufacturer, contract manufacturer, product revision, or market presentation. A commercial excipient assessment should therefore use the current package insert, DailyMed record, NDC listing, and approved or marketed product labeling for the relevant SKU.[2]

What excipients are important in a 12-hour pseudoephedrine tablet?

The core excipient strategy is a matrix or coated-tablet system that slows pseudoephedrine release without creating unacceptable variability in dissolution.

Common functional excipient categories include:

Excipient category	Typical function	Commercial relevance
Hydrophilic polymer	Forms a gel matrix and controls drug diffusion	Supports 12-hour release
Film former	Creates a rate-controlling coating or protects the tablet	Can improve release consistency
Microcrystalline cellulose	Diluent and compression aid	Improves tablet hardness and manufacturability
Povidone or similar binder	Promotes granule and tablet cohesion	Reduces friability
Sodium starch glycolate or related disintegrant	Controls breakup of non-rate-controlling portions	Helps manage release and tablet integrity
Magnesium stearate or alternative lubricant	Reduces sticking and ejection force	Excess can slow wetting and dissolution
Colloidal silicon dioxide	Improves powder flow	Supports high-speed compression
Talc or coating aid	Improves processing and coating performance	May affect surface properties
Opacifier and colorant	Product identification and light protection	Supports brand differentiation
Waxes or hydrophobic materials	Reduce water penetration and slow release	Useful in matrix or coating designs

A low-risk formulation normally uses well-characterized excipients with established pharmaceutical use. The highest technical risk is not excipient eligibility. It is the interaction between polymer level, tablet hardness, lubricant concentration, coating weight, particle size, and dissolution conditions.

Hydrophilic matrix strategy

A hydrophilic matrix can use a swellable polymer to create a gel barrier around pseudoephedrine. Drug release is controlled through hydration, diffusion, erosion, or a combination of those mechanisms.

Advantages include:

• Lower coating complexity.
• Lower equipment burden.
• Potentially lower manufacturing cost.
• Easy adjustment of release rate through polymer concentration and viscosity grade.

Risks include sensitivity to compression force, tablet porosity, polymer hydration, and changes in gastrointestinal conditions. A matrix tablet can also show lot-to-lot variation if granule moisture and particle-size distribution are not tightly controlled.

Film-coated or multiparticulate strategy

A coated tablet or multiparticulate system can provide more precise release control. Coated pellets, granules, or drug-containing particles can be compressed into a tablet or filled into a capsule.

This approach may provide:

• Better control of initial release.
• Reduced risk of dose dumping.
• Greater flexibility for combination products.
• Potential differentiation through abuse-deterrent or tamper-resistant design.

The tradeoff is higher process complexity, additional coating validation, and greater sensitivity to coating defects.

What formulation patents protect EQUALINE 12 Hour Decongestant?

Publicly available information does not establish a commercially important, product-specific patent estate for the EQUALINE-branded product. Pseudoephedrine hydrochloride is an old active ingredient, and standard extended-release tablet technologies are widely used in generic pharmaceuticals.

Relevant intellectual-property categories could include:

IP category	Likely importance to EQUALINE
Composition-of-matter patent	Negligible for pseudoephedrine
Conventional extended-release matrix	Generally weak or expired
Coated-particle release system	Potentially relevant if proprietary and unexpired
Combination product	May have narrower method or formulation claims
Manufacturing process	Could protect process know-how rather than block competitors
Packaging or anti-tampering system	More likely to be design or trade-secret value
Brand trademark	Relevant to EQUALINE branding, not formulation exclusivity

A patent review should search the manufacturer, labeler, formulation owner, and any contract manufacturing affiliate. It should also distinguish between patents listed in the FDA Orange Book and patents that do not qualify for listing.

What is the Orange Book status of EQUALINE 12 Hour Decongestant?

The Orange Book is primarily relevant to approved prescription drugs and certain NDA products. A monograph-compliant OTC pseudoephedrine product generally does not obtain market exclusivity through the Orange Book in the same manner as an NDA product.[3]

The commercial implications are direct:

• No meaningful NCE exclusivity applies.
• A conventional OTC pseudoephedrine product normally has no practical three-year clinical-investigation exclusivity.
• Paragraph IV litigation is unlikely to be the principal market-entry issue.
• Competitors can enter if they meet monograph, manufacturing, labeling, and applicable registration requirements.
• A product-specific NDA could create a different regulatory and exclusivity profile, but that would not describe the ordinary private-label OTC model.

The principal barriers are regulatory compliance, supply-chain execution, pseudoephedrine controls, and retail access.

When does EQUALINE 12 Hour Decongestant lose exclusivity?

EQUALINE does not appear to depend on a conventional patent expiration date or FDA exclusivity period. Its market protection is operational rather than statutory.

A practical exclusivity timeline is:

Period	Commercial position
Product launch	Retail access depends on labeler, manufacturer, and distributor approval
Current commercialization	Competes with brand and store-brand pseudoephedrine ER tablets
Patent expiry analysis	No central unexpired composition patent is expected
Generic entry	Already structurally available through other manufacturers
Long-term position	Depends on price, retailer placement, supply reliability, and consumer recognition

This structure makes EQUALINE vulnerable to price competition. A formulation improvement would need to create a measurable benefit, such as better dissolution consistency, fewer tablets damaged in transit, improved swallowability, or a meaningful combination-product advantage.

What FDA regulatory requirements affect the formulation?

The product must conform to the FDA OTC nasal-decongestant monograph and applicable current good manufacturing practice requirements.[1,4]

Key regulatory controls include:

• Correct active-ingredient identity and strength.
• Appropriate extended-release performance.
• Labeling consistent with OTC requirements.
• Stability through the labeled shelf life.
• Manufacturing under 21 C.F.R. Parts 210 and 211.
• Controls for content uniformity and dissolution.
• Packaging that supports required warnings and pseudoephedrine controls.
• Compliance with applicable state registration and reporting rules.

Pseudoephedrine products also face federal restrictions under the Combat Methamphetamine Epidemic Act. Retail sales are subject to daily and monthly transaction limits, identification requirements, logbook or electronic-record requirements, and storage or access controls depending on the seller and jurisdiction.[5]

An excipient change may be commercially attractive but still require substantial validation. The critical comparability package should include dissolution profiling, assay, content uniformity, impurities, tablet hardness, friability, moisture, stability, and packaging interaction studies.

What manufacturing and excipient barriers limit commercial entry?

The main manufacturing barriers are manageable but commercially important.

Release-rate reproducibility

Pseudoephedrine is highly water-soluble. Without adequate control, a matrix or coating can release the drug too quickly. Polymer viscosity, coating thickness, tablet porosity, and lubricant level require tight process control.

Dose dumping risk

Alcohol exposure, mechanical damage, excessive compression, or defective coating can alter release behavior. The formulation should be evaluated under stress conditions, including agitation, alcohol-containing media where relevant, and tablet crushing or mechanical abuse.

High-speed tableting

A private-label product must generally operate at low cost. Excipients should support high-speed compression, low sticking, predictable ejection, and acceptable friability. A formulation that performs well in development but requires slow compression has limited commercial value.

Supply continuity

A two-source strategy for the main polymer, diluent, lubricant, and coating materials can reduce interruption risk. However, replacing a critical polymer grade can alter dissolution and require comparability work.

Packaging controls

Pseudoephedrine may require behind-the-counter or controlled-access retail presentation. Unit-dose blister packaging can improve inventory control and reduce unauthorized access, but it may increase packaging cost compared with bottles.

What commercial opportunities exist for EQUALINE excipient innovation?

Lower-cost extended-release platform

The strongest near-term opportunity is a robust matrix formulation using widely available excipients. The objective is not novelty. It is a lower total cost of goods with stable dissolution across multiple manufacturing sites.

Potential levers include:

• Reduced coating weight.
• Direct compression rather than wet granulation.
• Standardized polymer grades.
• Lower tablet weight.
• Fewer specialty excipients.
• Improved tooling and compression speed.

Combination products

A pseudoephedrine extended-release tablet can be combined with an antihistamine, analgesic, or cough component. Combination products can support higher retail pricing and clearer seasonal merchandising.

The principal risks are interaction between release systems, more complex labeling, greater adverse-event exposure, and additional regulatory review.

Improved tablet usability

Potential differentiation includes a smaller tablet, smoother coating, better swallowability, or a scored presentation where legally and technically appropriate. These changes may improve consumer acceptance but are unlikely to create strong patent protection.

Packaging and retail compliance

Unit-dose blister packaging, controlled-access packaging, tamper-evident features, and retailer-compatible electronic identification systems can create commercial value. The benefit is operational rather than therapeutic.

Alternative decongestant positioning

The FDA determined that oral phenylephrine is not effective as a nasal decongestant at the monograph dose and proposed removing it from the OTC monograph.[6] This may increase retailer and consumer attention on pseudoephedrine products, although pseudoephedrine remains subject to stricter sales controls.

How does EQUALINE compare with Sudafed 12 Hour and store-brand competitors?

Factor	EQUALINE	Sudafed 12 Hour	Other store brands
Active ingredient	Pseudoephedrine ER	Pseudoephedrine ER	Usually pseudoephedrine ER
Primary advantage	Price and private-label placement	Brand recognition	Low price
Patent moat	Limited	Limited for mature product technology	Limited
Retail restrictions	Applicable	Applicable	Applicable
Excipient differentiation	Usually low visibility	May include proprietary manufacturing know-how	Usually cost-driven
Commercial risk	Retailer delisting and price pressure	Brand substitution and regulation	Supply reliability and margin compression
Main opportunity	Cost and availability	Brand premium	Lowest-cost compliant supply

Brand competition is strongest where consumers specifically request Sudafed. Store-brand products compete through price and retailer loyalty. EQUALINE's performance depends on maintaining distribution and avoiding stockouts during seasonal demand surges.

What generic launch risks exist for EQUALINE?

The product has high substitution risk because comparable pseudoephedrine extended-release products are already available. A new entrant could compete through:

• Lower manufacturing cost.
• More reliable supply.
• Retailer-exclusive packaging.
• Combination products.
• Improved tablet robustness.
• Private-label distribution.
• Multi-site manufacturing qualification.

The largest launch risks are not Paragraph IV litigation or biosimilar competition. They are monograph compliance, pseudoephedrine distribution restrictions, retailer onboarding, forecasting errors, and failure to match dissolution performance.

What patent litigation, settlement agreements, or biosimilar risks affect the product?

No material biosimilar risk applies because EQUALINE is a small-molecule oral tablet, not a biologic. No central product-specific Paragraph IV litigation or settlement structure is expected to define market access for a conventional OTC pseudoephedrine product.

Potential disputes would more likely involve:

• Trademark or trade-dress rights.
• Contract manufacturing obligations.
• Product liability.
• Labeling compliance.
• Retail distribution agreements.
• Trade-secret claims involving release-control processes.

What is the revenue exposure and commercial value of EQUALINE?

Product-specific revenue for EQUALINE is not generally disclosed as a separate public line item. The commercial value should be modeled through unit volume, retailer transfer price, gross margin, seasonal demand, and pseudoephedrine transaction constraints.

A useful sensitivity model is:

Variable	Downside driver	Upside driver
Unit volume	Retail restrictions and substitution	Cold-season demand
Net price	Store-brand price competition	Brand or retailer exclusivity
Gross margin	Specialty excipients and blister cost	Direct compression and scale
Supply	API or polymer shortages	Dual sourcing
Inventory	Short shelf-life or weak forecasting	Seasonal safety stock
Market access	Retailer delisting	Expanded private-label distribution

The product is more attractive as part of a broader OTC portfolio than as a standalone innovation asset. The best commercial thesis is a low-cost, reliable pseudoephedrine platform that can support multiple retailer labels and combination products.

Key Takeaways

• EQUALINE 12 Hour Decongestant is generally a pseudoephedrine hydrochloride extended-release OTC tablet.
• Its core value comes from controlled release, manufacturing consistency, price, and retail distribution.
• Conventional patent and Orange Book exclusivity are unlikely to provide meaningful protection.
• Hydrophilic matrix and coated-release systems are the main formulation options.
• Excipient changes should be evaluated through dissolution, stability, bioavailability, and process-comparability data.
• Pseudoephedrine sales controls are a larger commercial constraint than patent litigation.
• Commercial opportunities include low-cost matrix technology, combination products, improved packaging, and retailer-exclusive supply.
• Biosimilar risk is irrelevant; generic and private-label substitution risk is high.
• No product-specific revenue conclusion is supportable without separate sales disclosure.

FAQs

Is EQUALINE 12 Hour Decongestant a generic drug?

It is generally positioned as a store-brand or private-label equivalent of a pseudoephedrine extended-release product. It competes in a market with multiple generic and branded products.

Does EQUALINE 12 Hour Decongestant contain phenylephrine?

The 12-hour product is generally associated with pseudoephedrine hydrochloride, not oral phenylephrine. The exact active ingredient should be confirmed against the current package label for the relevant SKU.

Can a new company patent a pseudoephedrine extended-release formulation?

A new company may obtain narrow patents on a genuinely novel release system, manufacturing process, abuse-deterrent design, or combination product. Broad protection over pseudoephedrine or ordinary extended-release tablets is unlikely.

Are pseudoephedrine extended-release tablets subject to DEA controls?

Pseudoephedrine is not treated like a conventional prescription controlled substance, but federal law imposes regulated sales, purchase, identification, recordkeeping, and quantity limits because of its diversion risk.[5]

What is the strongest commercial differentiator for a competing product?

The strongest differentiators are reliable supply, lower cost, consistent 12-hour dissolution, retailer access, compliant packaging, and a useful combination product. Conventional excipient substitution alone is unlikely to justify a substantial price premium.

References

1. U.S. Food and Drug Administration. (n.d.). 21 C.F.R. § 341: Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use. Electronic Code of Federal Regulations.

2. U.S. National Library of Medicine. (n.d.). DailyMed: Current labeling for prescription and nonprescription drug products. https://dailymed.nlm.nih.gov/

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

4. U.S. Food and Drug Administration. (2019). Drug manufacturing and quality: Current good manufacturing practice. FDA.

5. U.S. Drug Enforcement Administration. (n.d.). Combat Methamphetamine Epidemic Act requirements for retail sales of scheduled listed chemical products. DEA.

6. U.S. Food and Drug Administration. (2024). FDA proposes removing oral phenylephrine from OTC monograph because current data do not support effectiveness as a nasal decongestant. FDA.